AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
Age and angina as predictors of quality of life after myocardial infarction - A prospective comparative study
Authors: Bengtsson, I Hagman, M Wedel, H
Citation: I. Bengtsson et al., Age and angina as predictors of quality of life after myocardial infarction - A prospective comparative study, SC CARDIOVA, 35(4), 2001, pp. 252-258
Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) Study
Authors: Ruilope, LM Salvetti, A Jamerson, K Hansson, L Warnold, I Wedel, H Zanchetti, A
Citation: Lm. Ruilope et al., Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) Study, J AM S NEPH, 12(2), 2001, pp. 218-225
Socioeconomic status and mortality in Swedish women: Opposing trends for cardiovascular disease and cancer
Authors: Cabrera, C Helgesson, O Wedel, H Bjorkelund, C Bengtsson, C Lissner, L
Citation: C. Cabrera et al., Socioeconomic status and mortality in Swedish women: Opposing trends for cardiovascular disease and cancer, EPIDEMIOLOG, 12(5), 2001, pp. 532-536
Changes in the use of medications after acute myocardial infarction: possible impact on mortality after myocardial infarction and long-term outcome
Authors: Herlitz, J Dellborg, R Karlson, BW Lindqvist, J Karlsson, T Sanden, W Sjolin, M Wedel, H
Citation: J. Herlitz et al., Changes in the use of medications after acute myocardial infarction: possible impact on mortality after myocardial infarction and long-term outcome, CORON ART D, 12(1), 2001, pp. 61-67
Insulin resistance and intima-media thickness in the carotid and femoral arteries of clinically healthy 58-year-old men. The Atherosclerosis and Insulin Resistance Study (AZR)
Authors: Bokemark, L Wikstrand, J Attvall, S Hulthe, J Wedel, H Fagerberg, B
Citation: L. Bokemark et al., Insulin resistance and intima-media thickness in the carotid and femoral arteries of clinically healthy 58-year-old men. The Atherosclerosis and Insulin Resistance Study (AZR), J INTERN M, 249(1), 2001, pp. 59-67
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol
Authors: Sever, PS Dahlof, B Poulter, NR Wedel, H Beevers, G Caulfield, M Collins, R Kjeldsen, SE McInnes, GT Mehlsen, J Nieminen, M O'Brien, E Ostergren, J
Citation: Ps. Sever et al., Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol, J HUM HYPER, 15, 2001, pp. S11-S12
CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease
Authors: Engaras, B Kewenter, J Nilsson, O Wedel, H Hafstrom, L
Citation: B. Engaras et al., CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease, EUR J SUR O, 27(1), 2001, pp. 43-48
Metoprolol controlled release/extended release in patients with severe heart failure - Analysis of the experience in the MERIT-HF study
Authors: Goldstein, S Fagerberg, B Hjalmarson, A Kjekshus, J Waagstein, F Wedel, H Wikstrand, J
Citation: S. Goldstein et al., Metoprolol controlled release/extended release in patients with severe heart failure - Analysis of the experience in the MERIT-HF study, J AM COL C, 38(4), 2001, pp. 932-938
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian cardiac outcomes trial
Authors: Sever, PS Dahlof, B Poulter, NR Wedel, H Beevers, G Caulfield, M Collins, R Kjeldsen, SE McInnes, GT Mehlsen, J Nieminen, M O'Brien, E Ostergren, J
Citation: Ps. Sever et al., Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian cardiac outcomes trial, J HYPERTENS, 19(6), 2001, pp. 1139-1147
Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study
Authors: Zanchetti, A Hansson, L Dahlof, B Elmfeldt, D Kjeldsen, S Kolloch, R Larochelle, P McInnes, GT Mallion, JM Ruilope, L Wedel, H
Citation: A. Zanchetti et al., Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study, J HYPERTENS, 19(6), 2001, pp. 1149-1159
Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study
Authors: Zanchetti, A Hansson, L Menard, J Leonetti, G Rahn, KH Warnold, I Wedel, H
Citation: A. Zanchetti et al., Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study, J HYPERTENS, 19(4), 2001, pp. 819-825
Risk factors for a major coronary event after myocardial infarction in theScandinavian Simvastatin Survival Study (4S) - Impact of predicted risk onthe benefit of cholesterol-lowering treatment
Authors: Wilhelmsen, L Pyorala, K Wedel, H Cook, T Pedersen, T Kjekshus, J
Citation: L. Wilhelmsen et al., Risk factors for a major coronary event after myocardial infarction in theScandinavian Simvastatin Survival Study (4S) - Impact of predicted risk onthe benefit of cholesterol-lowering treatment, EUR HEART J, 22(13), 2001, pp. 1119-1127
Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness - Main results from the beta-blocker cholesterol-lowering asymptomatic plaque study (BCAPS)
Authors: Hedblad, B Wikstrand, J Janzon, L Wedel, H Berglund, G
Citation: B. Hedblad et al., Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness - Main results from the beta-blocker cholesterol-lowering asymptomatic plaque study (BCAPS), CIRCULATION, 103(13), 2001, pp. 1721-1726
Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial
Authors: Wedel, H DeMets, D Deedwania, P Fagerberg, B Goldstein, S Gottlieb, S Hjalmarson, A Kjekshus, J Waagstein, F Wikstrand, J
Citation: H. Wedel et al., Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial, AM HEART J, 142(3), 2001, pp. 502-511
Losartan intervention for endpoint reduction in hypertension: The LIFE study
Authors: Dahlof, B Devereux, R de Faire, U Fyhrquist, F Nieminen, MS Ibsen, H Julius, S Kjeldsen, S Kristianson, K Lederballe-Pedersen, O Lindholm, LH Omvik, P Oparil, S Wedel, H
Citation: B. Dahlof et al., Losartan intervention for endpoint reduction in hypertension: The LIFE study, CLINICAL TRIALS IN HYPERTENSION, 2001, pp. 605-624
Long-term mortality after acute myocardial infarction in relation to prescribed dosages of a beta-blocker at hospital discharge
Authors: Herlitz, J Dellborg, M Karlson, BW Lindqvist, J Wedel, H
Citation: J. Herlitz et al., Long-term mortality after acute myocardial infarction in relation to prescribed dosages of a beta-blocker at hospital discharge, CARDIO DRUG, 14(6), 2000, pp. 589-595
Incidence of chronic myeloproliferative disorders in the city of Goteborg,Sweden 1983-1992
Authors: Ridell, B Carneskog, J Wedel, H Vilen, L Dufva, IH Mellqvist, UH Brywe, N Wadenvik, H Kutti, J
Citation: B. Ridell et al., Incidence of chronic myeloproliferative disorders in the city of Goteborg,Sweden 1983-1992, EUR J HAEMA, 65(4), 2000, pp. 267-271
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The LIFE study
Authors: Kjeldsen, SE Dahlof, B Devereux, RB Julius, S de Faire, U Fyhrquist, F Ibsen, H Kristianson, K Lederballe-Pedersen, O Lindholm, LH Nieminen, MS Omvik, P Oparil, S Wedel, H
Citation: Se. Kjeldsen et al., Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The LIFE study, AM J HYPERT, 13(8), 2000, pp. 899-906
Differentiated long-term effects of intentional weight loss on diabetes and hypertension
Authors: Sjostrom, CD Peltonen, M Wedel, H Sjostrom, L
Citation: Cd. Sjostrom et al., Differentiated long-term effects of intentional weight loss on diabetes and hypertension, HYPERTENSIO, 36(1), 2000, pp. 20-25
Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure - The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)
Authors: Hjalmarson, A Goldstein, S Fagerberg, B Wedel, H Waagstein, F Kjekshus, J Wikstrand, J El Allaf, D Vitovec, J Aldershvile, J Halinen, M Dietz, R Neuhaus, KL Janosi, A Thorgeirsson, G Dunselman, PHJM Gullestad, L Kuch, J Herlitz, J Rickenbacher, P Ball, S Gottlieb, S Deedwania, P
Citation: A. Hjalmarson et al., Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure - The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF), J AM MED A, 283(10), 2000, pp. 1295-1302
Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy - The randomized evaluation of strategies for left ventricular dysfunction pilot study
Authors: Cirillo, W Decanini, R Coelho, OR Avezum, A Peixoto, MSP Piegas, LS Neto, JMR Paiva, M Carvalho, AC de Almeida, DR Fernandes, IML Malavasi, MC Pavanello, R Canesin, M Ishii, S Barretto, ACP Imrie, J Moore, R Woo, K Bernstein, V Mizgala, HF Mooney, S Hilbich, D Kuritzky, R Rupka, DW Blackwell, MM Breakwell, L Kornder, JM Pearce, SA Polasek, P Richardson, PM Grant, J Isaac, D Beresford, P Giannoccaro, P Roth, D Greenwood, P Muzyka, T Prosser, A Brass, N Hui, W Kvill, L Goeres, M MacDonald, K Senaratne, M Hill, L Humen, D Teo, KK Habib, N Habib, N Teekasingh, S MacKenzie, J McEwen, B Morris, A Dhair, A Lai, C Kwiatkowski, K Brugos, J Nawaz, S Andrews, J Moe, G Freskiw, K Gilbert, B Morgan, CD Bozek, B Halperin, F Ricci, AJ Singh, N Cappelli, G Boyne, T Fallen, E Panju, A Woodcock, G Kent, E Kitching, AD Sullivan, H Tomson, D McKelvie, RS Tsuyuki, RT Yusuf, S Chan, YK Thomson, D Arnold, JMO Hurwitz, G Miles, R Baker, A Haspect, A Smith, S Bedard, J Lavoie, L Dufort, L Harvey, R Lepage, S Elstein, E Fitchett, D Serpa, A Day, L Racine, N Savard, D Sestier, F Gosselin, G Rouleau, JL White, M Whittom, L Kiwan, G Kouz, SM Laforest, M Ouimet, H Carmichael, P Lenis, J Auger, P Grondin, F Saulnier, D Campeau, J Dupuis, R Lauzon, C Genest, M Robitaille, NM Beaudoin, J Belanger, N Houde, G Talbot, P Cossett, J Koilpillai, C Sheridan, WJ Tobin, M Sussex, B Ascoli, G Fraticelli, A Paciaroni, E Como, CO Belluschi, R Ruffa, F Tettamanti, F Cobelli, F Salvucci, F Arpesella, R Campana, C Gavazzi, A Cirrincione, V Ingrilli, F Sciortino, E Boccanelli, A Cacciatore, G Menichelli, M Bosimini, E Giannuzzi, P Marcassa, C Porcu, M Salis, S Sanna, A Comerio, G Gronda, E Mangiavacchi, M Moccetti, T Pasotti, E Sessa, F Levy, WC Probstfield, J Thompson, J Gramberg, M Grover, J Towery, D Ogunyankin, K Singh, BN Celano, J Graham, S Kohn, RM Pande, P Sass, A Wiener, RS Rydzinski, S Starling, RC Young, J Hays, L Naftilan, A Miller, A Varga, A Wofford, R Barnhill, S Brito, RD Harris, L Haspect, A Cristina, T Jarosz, M Kellen, J Kingry, C Letterer, R La Forge, D Liuni, C MacKenzie, J Magi, A Stevens, K Squires, P Yusuf, S Rouleau, JL Maggioni, A Arnold, JMO Avezum, A Burns, R Floras, J Gavazzi, A Held, P Hjalmarson, A Isaac, D Latini, R Lindgren, E McKelvie, RS Piegas, LS Pericak, D Pogue, J Probstfield, J Smith, S Swedberg, K Teo, KK Tsuyuki, RT Vint-Reed, C Wang, Y White, M Wiecek, EM Young, J Johnstone, D Armstrong, PW Packer, M Wedel, H Teo, KK Gavazzi, A Tsuyuki, RT White, M McKelvie, R Anderson, M Holadyk-Gris, I Kucemba, K MacKay, J McKelvie, RS Micks, M Pericak, D Pogue, J Reeve, S Robinson, L Tsuyuki, RT Tucker, J Wiecek, EM Wang, Y Yusuf, S Cernacek, P Joyal, M Poitras, N Rouleau, JL White, M Sirois, P Bevilacqua, M Latini, R Masson, S Torri, M Hall, C Burns, RJ Heeney, T Tadros, S White, M Yusuf, S McKelvie, RS Pericak, D Young, J Latini, R Pogue, J Burns, RJ Probstfield, J Tsuyuki, RT Maggioni, AP Avezum, A Rouleau, JL
Citation: W. Cirillo et al., Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy - The randomized evaluation of strategies for left ventricular dysfunction pilot study, CIRCULATION, 101(4), 2000, pp. 378-384
Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering
Authors: Pedersen, TR Wilhelmsen, L Faergeman, O Strandberg, TE Thorgeirsson, G Troedsson, L Kristianson, J Berg, K Cook, TJ Haghfelt, T Kjekshus, J Miettinen, T Olsson, AG Pyorala, K Wedel, H
Citation: Tr. Pedersen et al., Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering, AM J CARD, 86(3), 2000, pp. 257-262
Standard serum concentrations and normal fluctuations of CEA, CA 50 and CA242 during twelve months in men and women aged 60-64 years without malignant disease
Authors: Engaras, B Hafstrom, L Kewenter, J Nilsson, O Wedel, H
Citation: B. Engaras et al., Standard serum concentrations and normal fluctuations of CEA, CA 50 and CA242 during twelve months in men and women aged 60-64 years without malignant disease, EURO J SURG, 165(2), 1999, pp. 110-116
Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: The SOS Intervention Study
Authors: Sjostrom, CD Lissner, L Wedel, H Sjostrom, L
Citation: Cd. Sjostrom et al., Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: The SOS Intervention Study, OBES RES, 7(5), 1999, pp. 477-484
Similar risk reduction of death of extended-release metoprolol once daily and immediate-release metoprolol twice daily during 5 years after myocardial infarction
Authors: Herlitz, J Dellborg, M Karlson, BW Lindqvist, J Sanden, W Svensson, H Sjolin, M Wedel, H
Citation: J. Herlitz et al., Similar risk reduction of death of extended-release metoprolol once daily and immediate-release metoprolol twice daily during 5 years after myocardial infarction, CARDIO DRUG, 13(2), 1999, pp. 127-135
Risultati: 1-25 | 26-33